AVRO AVROBIO Inc.

13.87
-0.13  -1%
Previous Close 14
Open 13.97
Price To Book 4.73
Market Cap 439,169,028
Shares 31,663,232
Volume 168,261
Short Ratio
Av. Daily Volume 224,033
Stock charts supplied by TradingView

NewsSee all news

  1. AVROBIO Announces First Patient Dosed in Phase 1/2 Trial of Gene Therapy for Cystinosis

    Investigational Therapy Designed to Engineer Patients' Own Stem Cells to Produce Essential Protein AVROBIO, Inc. (NASDAQ:AVRO) (the "Company") today announced that the first patient has been dosed in the Company's

  2. AVROBIO, Inc. to Present at Chardan's 3rd Annual Genetic Medicines Conference

    AVROBIO, Inc. (NASDAQ:AVRO), a Phase 2 clinical-stage gene therapy company, today announced that Geoff MacKay, President and CEO of AVROBIO, will present at Chardan's 3rd Annual Genetic Medicines Conference on Monday,

  3. AVROBIO, Inc. to Present at Upcoming Investor Conferences

    AVROBIO, Inc. (NASDAQ:AVRO) a Phase 2 clinical-stage gene therapy company, today announced that members of its senior management team are scheduled to participate in five upcoming investor conferences. Citi's 14th

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 1/2 commencement of dosing announced October 8, 2019.
AVR-RD-04
Cystinosis
Phase 1/2 trial planned for 1Q 2020.
AVR-RD-02
Gaucher disease
Phase 2 preliminary data released July 15, 2019.
AVR-RD-01 (FAB-201)
Fabry disease

Latest News

  1. AVROBIO Announces First Patient Dosed in Phase 1/2 Trial of Gene Therapy for Cystinosis

    Investigational Therapy Designed to Engineer Patients' Own Stem Cells to Produce Essential Protein AVROBIO, Inc. (NASDAQ:AVRO) (the "Company") today announced that the first patient has been dosed in the Company's

  2. AVROBIO, Inc. to Present at Chardan's 3rd Annual Genetic Medicines Conference

    AVROBIO, Inc. (NASDAQ:AVRO), a Phase 2 clinical-stage gene therapy company, today announced that Geoff MacKay, President and CEO of AVROBIO, will present at Chardan's 3rd Annual Genetic Medicines Conference on Monday,

  3. AVROBIO, Inc. to Present at Upcoming Investor Conferences

    AVROBIO, Inc. (NASDAQ:AVRO) a Phase 2 clinical-stage gene therapy company, today announced that members of its senior management team are scheduled to participate in five upcoming investor conferences. Citi's 14th